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ABSTRACT
Proteomics informed by transcriptomics (PIT), in
which proteomic MS/MS spectra are searched
against open reading frames derived from de novo
assembled transcripts, can reveal previously un-
known translated genomic elements (TGEs). How-
ever, determining which TGEs are truly novel, which
are variants of known proteins, and which are simply
artefacts of poor sequence assembly, is challeng-
ing. We have designed and implemented an auto-
mated solution that classifies putative TGEs by com-
paring to reference proteome sequences. This al-
lows large-scale identification of sequence polymor-
phisms, splice isoforms and novel TGEs supported
by presence or absence of variant-specific peptide
evidence. Unlike previously reported methods, ours
does not require a catalogue of known variants, mak-
ing it more applicable to non-model organisms. The
method was validated on human PIT data, then ap-
plied to Mus musculus, Pteropus alecto and Aedes
aegypti. Novel discoveries included 60 human pro-
tein isoforms, 32 392 polymorphisms in P. alecto, and
TGEs with non-methionine start sites including tyro-
sine.
INTRODUCTION
RNA sequencing (RNA-Seq) followed by de novo transcript
assembly provides unprecedented insight into gene expres-
sion in a given sample, even if the species under study has
a poorly annotated genome (1). However, an assembled
transcript might not correspond to a functional protein, ei-
ther for biological reasons or because of sequencing or as-
sembly errors. To resolve this ambiguity we developed the
PIT (proteomics informed by transcriptomics) methodol-
ogy in which spectra acquired from liquid chromatography
tandem mass spectrometry (LC–MS/MS) proteomics are
searched against open reading frames (ORFs) derived from
de novo assembled transcripts acquired from the same sam-
ple (2). Using sample-specific ORFs allows unbiased identi-
fication of translated genomic elements (TGEs), unlike tra-
ditional proteomics where spectra are searched against ref-
erence protein sequences. PIT therefore allows discovery of
new TGEs, including variants of known proteins, and can
provide confirmation of transcriptomic observations.
While we have previously published software pipelines for
PIT analysis (3), their output is essentially a list of iden-
tified TGE sequences (i.e. ORFs supported by peptide ev-
idence). Further post-processing is needed to confidently
classify each TGE identification and the sample-specific
events that underpin them, such as single amino acid poly-
morphisms (SAPs), insertions and deletions (INDELs) and
alternative splicing. Such events have been associated with
disease phenotypes (4–8) and gene regulation (9–11). The
significance of single nucleotide polymorphisms (SNPs) in
disease phenotypes has prompted several studies to confirm
SAPs using mass-spectrometry data (12–14). Many alter-
native splice isoforms have been observed using RNA-Seq
(13,15) but it is unclear how many are translated. A com-
mon method for confirming variations at protein level has
been to search spectra against a reference proteome aug-
mented with an existing database of known variations or
variations identified fromRNA-Seq data, although not nec-
essarily from the same sample (13,16–20). The disadvantage
of relying on existing databases is that novel protein variants
cannot be found––a particular limitation for non-model or-
ganisms where databases are incomplete or unavailable.
Here, we present a TGE classification pipeline that gener-
ates variation information directly from RNA-Seq data for
each sample, and seeks to confirm this at peptide level us-
ing proteomics data from the same sample (Figure 1A and
B). The result is amolecular survey of unprecedented detail,
with TGEs simultaneously classified into groups including
novel proteins, known proteins, protein isoforms and pro-
teins with SAPs and other polymorphisms.
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Figure 1. PIT pipeline, now including classification of TGEs. (A) RNA-Seq assembly begins with the Trinity de novo transcript assembler. PASA is then used
to assemble spliced alignments and identify alternative splicing events at transcript level. Transdecoder is used to predict ORFs from PASA’s transcripts.
(B) TGEs are classified, based on sequence similarity to an existing proteome, into four main classes, (i) known protein or isoform, (ii) known protein or
isoform with polymorphisms, (iii) novel isoforms and (iv) novel TGE. Within these main classes there are four polymorphism categories and sixteen novel
isoform classes. We look for supporting peptides from the mass spectrometry (MS) data to verify these events at protein level. Variation information and
peptide evidence for all the identified TGEs is output and deposited in a database called PITDB. (C) Nomenclature of polymorphism types derived from
BLAST alignments used in this paper––see main text for details.
MATERIALS AND METHODS
Data
The pipeline was evaluated on data acquired from a human
(HeLa) cell line infected with adenovirus (2), then applied
to data from three other experiments: Pteropus alecto kid-
ney cell line PaKiT03 exposed to Nelson Bay orthoreovirus
(NBV) (21),Musmusculus fibroblast L929 cell line (22), and
immortalised Aedes Aegypti cell line Aag2 (23). Details of
the proteomics and RNA-Seq data acquisition, and infor-
mation about where to find this data, are summarised in
Supplementary Table S1. The results generated by applying
our pipeline to the data are available in the specially cre-
ated database PITDB (21) [http://pitdb.org] (experiment ac-
cession numbers EXP000001, EXP000003, EXP000004 and
EXP000008).
RNA-Seq transcript assembly and protein identification
RNA-Seq reads were initially assembled de novo using Trin-
ity (24). Default Trinity read trimming was used along
with ‘trimmomatic’ and ‘normalize reads’ for quality con-
trol. Clusters of overlapping Trinity transcripts were assem-
bled into maximal alignment assemblies using the Program
to Assemble Spliced Alignments (PASA) (25). PASA runs
the seqclean (26; https://sourceforge.net/projects/seqclean/)
tool to discard low quality sequences, find evidence of
polyadenylation, strip poly-A tails and trim vectors. It
then maps remaining transcripts to a reference genome
using a spliced alignment process that infers the intron-
exon structure of the parent gene. Reference genomes used
were hg38 (human), mm10 (M. musculus), ASM32557v1
(P. alecto) and aedes-aegypti-liverpoolscaffoldsaaegl3 (A.
aegypti). Any transcripts that do not map to the selected
genome assembly (e.g. from viruses) are discarded at this
stage. Applying PASA reduces the number of incomplete
ORFs and duplicate transcripts, minimising search space
in subsequent peptide identification (Supplementary Figure
S1).
Transdecoder (27) was then used for six frame translation
of the transcripts, using the default universal genetic code
in which methionine is the start codon. Transdecoder as-
signs ORFs to one of four classes: complete, 5prime partial,
3prime partial and internal, based on existence of start and
stop codon in the transcript (Supplementary Figure S2).
Missing start or stop codons may be due to poor sequence
assembly, or alternative start/stop codons. One transcript
may produce multiple ORFs, and transcripts with identical
protein coding regions (but different untranslated regions)
can produce identical ORFs. Duplicate ORFs are retained
prior to protein identification to preserve transcript rela-
tionships, but are merged into a single TGE when reporting
results.
MS-GF+ (28) was used for peptide spectrum match-
ing, followed by mzidentML-lib (29) for FDR calculation,
thresholding, and protein grouping. MS-GF+ computes
PSM and peptide level q-value using a target-decoy (30) ap-
proach. The search database for each sample contained the
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ORFs obtained from the RNA-Seq data for that sample,
plus contaminant sequences from the common Repository
of Adventitious Proteins (http://www.thegpm.org/crap).We
used 1% global PSM-level FDR and only ORFs with at
least two identified peptides were retained as TGEs.
Classification of observed TGEs by ORF homology
TGEs were classified according to their sequence similarity
to a reference proteome using BLAST. BLOSUM80 sub-
stitution matrix was used as it is best suited for compar-
ing closely related sequences (31). UniProt complete pro-
teomes were used as the reference for all species except A.
aegypti, for which a superior proteome was taken from Vec-
torBase. TGEs with 100% sequence identity to a reference
protein are classed as known protein, or known protein iso-
form if the sequence is flagged as an isoform in the reference
database. A TGE that does not map to a reference protein
with a BLAST e-value below 1× 10−30 is classified as novel.
Polymorphic proteins. TGEs are classed as known protein
with polymorphism when the BLAST alignments are not
identical but have e-value below 1× 10−30 and cover the full
length of the TGE and the reference protein by introducing
polymorphisms such as SAPs, alterations (polymorphisms
involving multiple AAs––labeled as ALT), insertions and
deletions. Similarity of polymorphisms is identified from
the BLAST alignment midline string, as shown in Figure
1C. If an AA is replaced by a chemically similar AA, we
call it a SSAP (similar SAP). The same applies to alteration
events: an ALT where all AAs have similar chemical prop-
erties to their reference sequence counterpart is assigned to
a separate category called similar alteration (SALT).
Isoform classification. Polymorphisms involving more
than nineAAs are assigned to a separate internal alternative
splice variant group (labeled SV), accounting for alternative
splicing events such as exon skipping, intron retention and
mutually exclusive exons. The nine AA threshold is gener-
ally accepted as the shortest length of an exon (∼99% of
protein coding exons are longer than 27 bp). Some TGEs do
not map to the full length of the reference protein, or they
extend beyond the reference protein. They may also contain
polymorphisms. These TGEs are putative novel isoforms,
which we categorize into fifteen different classes depending
on the nature and location of the variation, as shown in Fig-
ure 2A. These classes describe variations at the N-terminal
(5-prime end), the C-terminal (3-prime end), or both ends,
of the TGE.
Confirmation of protein variants using peptide evidence
Applying the aforementioned classification strategy to
TGEs in this study resulted in the majority being classified
as putative novel isoforms and variant proteins. Evidence
underpinning each TGE observation was at least two pep-
tide observations mapped to the ORF, but not necessarily
to variations within the ORF. Many supposedly novel vari-
ants could therefore be due toRNA-Seq errors or poor tran-
script assembly affecting regions of the ORF not covered by
peptide identifications. To separate these from true TGEob-
servations, two methods were applied – a simple approach
that demands variant-specific peptides, and a probabilistic
scoring approach in which the likely presence of a variant is
computed with respect to the reference alternative.
Variant-specific peptides. Unlike previous studies that rely
on prior knowledge of SNPs and splice sites, we identify
variations within our TGE classification pipeline and check
for peptides mapping specifically to the variant areas of the
TGEs on a sample by sample basis. The majority of these
peptides are shared with other TGEs in the sample, so we
report peptides uniquely mapping to the variation region
separately as this is stronger evidence of the variation.
Scoring of variants using predicted peptide detectability.
Given that the sequence coverage of LC-MS/MS pro-
teomics is generally low (e.g. ∼17% for known human pro-
teins in this study) it is arguably too conservative to demand
peptide evidence for every variant. Some variants are cov-
ered by a single peptide, whichmay not be detectable byMS.
A more advanced strategy was therefore implemented, in
which predicted peptide detectability, together with peptide
identification confidence (represented by q-value), is used
to determine the probability that a novel protein variant is
more likely to be present in the sample than its correspond-
ing reference protein.
We used an enhanced version of CONSeQuence (32)
to calculate a sequence-based detectability score for every
tryptic peptide that could be identified in the sample (as
trypsin was used for proteolysis in all samples), then cali-
brated these to a sample-specific detection score (s) using a
transform function built using empirical peptide detectabil-
ity information from ORFs in the sample that had already
been identified as known proteins. By comparing the com-
bined probability of detection of the set of peptides, R =
{r1, r2 . . . rn}, that uniquely describe the reference protein
against the set of peptides,V= {v1, v2 . . . vm}, that describe
the protein variant it is possible to predict which is most
likely to be present in the sample. The details of this calcu-
lation are shown in Equation (1), and an example of its use
is shown in Figure 2B.
scorevariant = 1|V|+|R|
( ∑
∀a∈A
(1 − qa)
− ∑
∀b∈B
1−qb
4 +
∑
∀b∈B′
sb
8 −
∑
∀a∈A′
sa
8
) (1)
where A is the set of identified peptides from V, B is the set
of identified peptides from R, A′ is the set of unidentified
peptides in V and B′ is the set of unidentified peptides in R.
An equivalent equation is used to compute scorereference
scorereference = 1|R|+|V|
( ∑
∀b∈B
(1 − qb)
− ∑
∀a∈A
1−qa
4 +
∑
∀a∈A′
sa
8 −
∑
∀b∈B′
sb
8
) (2)
The score, scorevariant, for the TGE is calculated by con-
sidering only peptides that cover variant regions of the pro-
tein. Scores are assigned to each of these peptides as follows.
Peptides from the TGE are given a score of 1 – q (where
q is the lowest q-value for that peptide) if they are identi-
fied in the sample or –s/8 if they are not identified. Pep-
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Figure 2. (A) Classification of TGEs based on BLAST alignment to UniProt proteome (including isoforms) of the species under study. TGEs with 100%
sequence map to UniProt proteins are labelled as known proteins or known isoforms. TGEs with BLAST e-value above 1 × 10−30 or that do not map to a
UniProt protein are classified as novel. The remaining TGEs are classified into one of 17 types based on location, length and type of variation. (B) Example
of scoring a putative novel isoform based on its mapping to the most homologous protein found by BLAST (ODB2 HUMAN). Only peptides not shared
between the TGE and reference are used to compute the scores of the TGE and the reference protein, using Equation (1).Q-value scores and sample-specific
detectability scores (SS) are used for identified and unidentified peptides respectively. In this case, the TGE score exceeds that of the reference sequence,
suggesting we have a novel variant of ODB2. (C) Identified TGEs of each type supported by peptide evidence, and unique peptide evidence in parentheses.
The proportion of novel findings is higher in species with less well annotated genomes.
Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gky295/4990017
by University of Bristol Library user
on 03 May 2018
Nucleic Acids Research, 2018 5
tides from the reference sequence are given a score of (1
– q)/4 if they are identified in the sample or –(s/8) if they
were not identified. The sum of peptide scores for the ref-
erence sequence is then subtracted from the sum of pep-
tide scores for the TGE and normalised for peptide count
to give the final TGE score. A similar equation is used to
calculate scorereference (Equation 2). The denominators of
unidentified peptides were set to 8 to compensate for an an-
ticipated LC-MS/MS peptide coverage of 12.5%. The de-
nominator of 4 is used to ensure that the difference between
scorevariant and scorereference is small when both reference and
variant-specific peptides are observed, indicating that both
sequences are likely to exist in the sample.
The scorevariant and scorereference are calculated separately
so that the magnitude of the difference between them can
be used to accommodate situations where both versions of
the sequence may be present. Applying a threshold to this
difference can separate confidently classified variants from
reference proteins. Unless otherwise stated, we report TGEs
as variants when scorevariant > scorereference. More detail re-
garding the scoring pipeline can be found in Supplementary
Figure S3.
Validation of variant scoring method using human data.
PIT data was processed in the absence of prior protein vari-
ation information (i.e. TGE classification BLASTed against
the UniProt canonical proteome only) such that all ob-
served isoforms would be classified as novel isoforms (Sup-
plementary Figure S4). Separately, TGE classification was
performed by BLASTing against the UniProt human pro-
teome including known isoforms. Comparing the list of
novel isoforms from the first classification with the list of
identified known isoforms from the second classification in-
dicated the ability of the classification pipeline to identify
isoforms in the absence of prior knowledge.
Rating TGEs by available evidence
The overall confidence in the presence of an individual TGE
can be assessed by considering all the aforementioned ev-
idence collectively. For example, a list of observed TGEs
can be ranked using a rating system such as that shown in
Supplementary Table S2, where higher ratings are awarded
to TGEs with more rigorous forms of evidence such as a
unique PSM covering a variant region. This allows identi-
fied TGEs to be prioritised for further evaluation or valida-
tion.
RESULTS AND DISCUSSION
TGE classification
Results for all four species are summarised in Table 1, with
sample-specific breakdowns provided in SupplementaryTa-
bles S3-S5. Prior to considering variation-specific peptide
evidence, the majority of putative TGEs are classified as
novel isoforms, or known proteins with sequence polymor-
phism. Only 39% of putative TGEs from the human dataset
have 100% sequence similarity to reference protein, a pro-
portion that is lower still for A. aegypti (36%),M. musculus
(10%) and P. alecto (∼3%). ForM. musculus and P. alecto,
PIT identifies significantly more sequences compared to the
standard database search, probably due to PIT’s ability to
account for sample specific variations. However, the num-
ber of protein variations is likely to be a significant overesti-
mate as the TGEs are not necessarily supported by variant-
specific peptide evidence at this stage.
Variations supported by simple peptide evidence
The proportion of variations with variant-specific peptide
evidence varied greatly among species. Only a small mi-
nority of those in Table 1 have isoform specific peptides
(∼2% for human and M. musculus; ∼20% for P. Alecto
and A. Aegypti, reflecting the relative annotation quality
of these species). The distribution of identified isoforms
with variant-specific evidence among the various types is
summarised in Figure 2C (numbers in parentheses indicate
TGEs that meet the more conservative criteria of having
unique peptide evidence). Besides identifying peptides from
the variant regions, we found junction peptides for TGEs
from alternative and extended isoform classes. Themajority
of these junction peptides support alternative sequence vari-
ations.Many of these junction peptides are also unique pep-
tides (33–40% for the non-human datasets). This demon-
strates that the PIT pipeline is capable of high throughput
discovery of novel isoforms in the absence of prior informa-
tion about gene structure.
Regarding polymorphisms, human and M. musculus
have the lowest percentage of peptide-supported polymor-
phisms, only 5% and 7% respectively, whereas A. aegypti
and P. alecto have 15% and 23%. These were found in all
variant TGE classes, and in known proteins (counted sep-
arately in Table 1). Peptide supported polymorphisms are
shown for each species in Figure 3A. The total number of
polymorphisms range from just 60 for human, through to
32 392 for P. Alecto, reflecting the relative quality of the ref-
erence proteomes for these species. This suggests significant
scope for improving the P. Alecto reference proteome, by
using the polymorphisms identified by PIT to correct exist-
ing protein sequences predicted from an imperfect reference
genome.
Alternative start codons
The majority of TGEs classified as known protein were
from ORFs classified as complete by Transdecoder (see Ta-
ble 1), suggesting that many incomplete ORFs are due to
poor sequence assembly. However, some proteins do not
start with methionine so Transdecoder incompleteness does
not necessarily indicate an erroneousORF.Alternative start
codons are found in Swiss-Prot for all the species in this
study except A. aegypti. Our results include several non-
methionine starts with peptide evidence (often unique pep-
tide evidence) for all the species in this study (Figure 3B).
To avoid the possibility that an alternative start is called
due to the N-terminus of a truncated ORF coinciding with
a tryptic cleavage site, we discounted all TGEs with alter-
native starts where the reference protein has lysine or argi-
nine at the preceding position. The highest number of non-
methionine start codons supported by peptide evidence are
observed for P. alecto, most of which are valine or alanine.
We identified TGEs with N-terminus methionine removed,
which is significant for function and stability (33).
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Table 1. Overview of PIT TGE classification results
Dataset (number of samples in parentheses)
Homo
sapiens
(1)
Mus
muscu-
lus
(8)
Pteropus
alecto
(9)
Aedes
aegypti
(1)
Total spectra 210,560 293,894 350,890 829,093
Standard search Peptides 24,187 23,151 22,554 58,336
PAGs (protein ambiguity groups) 3,011 3,536 3,270 4,743
Total proteins 12,589 14,107 3,522 5,692
SwissProt Canonical 3,302 3,534 2 71
Isoform 3,365 1,344 0 79
TrEMBL 5,922 9,229 3,520 5,542
PIT search Peptides 21,612 24,297 23,875 52,221
PAGs 2,646 2,814 2,701 4,394
Total TGEs 3,504 24,602 28,311 5,488
TGEs mapping to SwissProt Canonical Total 1,134 1,270 0 77
Complete ORF 1,134 1,268 0 77
Isoform Total 197 195 0 1
Complete ORF 197 193 0 1
TGEs mapping to TrEMBL Total 38 925 765 1,939
Complete ORF 38 915 756 1,930
Putative novel isoform SwissProt Total 1,815 12,351 0 57
Complete ORF 174 1,864 0 20
Score 363 707 0 9
With specific peptide evidence 50 357 0 11
With unique specific peptide ev. 24 76 0 7
TrEMBL Total 233 9,194 26,328 3,080
Complete ORF 30 1,643 5,700 1,077
Score 92 488 5,092 891
With specific peptide evidence 10 390 4,735 903
With unique specific peptide ev. 3 82 1,452 428
Known protein with SwissProt Total 47 278 0 4
polymorphism Complete ORF 21 92 0 4
Score 7 14 0 0
With specific peptide evidence 1 6 0 0
With unique specific peptide ev. 1 3 0 0
TrEMBL Total 8 187 251 97
Complete ORF 5 86 95 85
Score 0 31 25 32
With specific peptide evidence 0 16 21 24
With unique specific peptide ev. 0 6 13 12
Novel TGE Total 32 202 967 233
Complete ORF 3 38 236 61
With unique peptide evidence 0 18 283 131
To allow comparison with standard proteomics methods, peptide and protein identification was also performed for each species by searching directly
against the reference proteome––the results of this are shown in the top (standard search) portion of the table. Throughout the table, identified proteins are
shown based on the source reference sequence: Swiss-Prot or TrEMBL. Swiss-Prot proteins are further divided into two groups, canonical and isoform.
TGEs with exact sequence map to reference proteins are classed as known proteins. TGEs not mapping to any reference proteins or with e-value above the
threshold are classified as novel TGEs. The remaining TGEs are classified as known proteins with polymorphism, or novel isoforms of known proteins. The
novel isoformTGEs are further separated into 16 classes and reliability of this annotation is verified by isoform-specific peptide evidence (see Supplementary
Table S5 for details). Peptide and protein counts reported in the table are unique sequences across all the samples for datasets with multiple samples and
average PAG (protein ambiguity group) counts are reported for these cases.
Validation of variant scoring method using human data
Our scoring-based classification method identified 76
known isoforms of the 197 found to be present in the sam-
ple during the evaluation process. These known isoforms
are supported by at least two peptides but, as in any pro-
teomics experiment, their presence in the sample cannot be
proven definitively without laboratory validation. The scor-
ing method identifies 42 known isoforms that the simple
peptide evidence approach missed, but fails to classify three
known isoforms reported by the simple peptide evidence ap-
proach (Figure 4A). Thesemissed isoformswere due to pep-
tide identifications from the reference having higher confi-
dence than from the variant, and failure to observe highly
detectable variant-specific peptides. A ROC curve (Figure
4B) shows the performance of the scoring method using
known isoforms identified from the PIT search. Novel pro-
tein variants confirmed by variant-specific peptides is the
best way to confirm their presence in the sample without
separate laboratory validation, therefore we used known
isoforms confirmed by variant-specific peptide evidence as
the gold standard for the validation process and observed an
area under the curve (AUC) of 0.90. Figure 4C shows how
increasing the score difference threshold reduces the num-
ber of TGEs classified, but increases the proportion of those
confirmed as isoforms present in the sample. Protein am-
biguity group analysis shows that known isoforms usually
share peptides with other variants of the protein, making
their presence ambiguous. This evaluation exercise shows
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Figure 3. (A) Overview of polymorphisms with variation-specific peptide
evidence, for each species. (B) Distribution of alternative start codons con-
firmed by peptide evidence for different species. For context, 172 and 166
Swiss-Prot proteins have alternative starts for human andM. musculus re-
spectively. Swiss-Prot contains only two proteins for P. alecto, and both
start with valine.
that the scoring method can significantly increase the num-
ber of confident novel isoform identifications compared to
the simple variation-specific peptide evidence approach.
Scoring variants using predicted peptide detectability
For the human dataset, application of the scoring method
with a zero threshold suggests that 455 out of 2048 puta-
tive novel isoforms are indeed novel isoforms, and seven
out of 55 putative known proteins with polymorphisms
are also confirmed (Supplementary Figure S5). As in the
evaluation, the scoring method classifies more TGEs than
the simple variant-specific peptide evidence method, and
there is a significant overlap between the two methods (Fig-
ure 4D). Except for one TGE each from P. alecto and hu-
man, the remaining TGEs supported by junction peptides
were classified as variants using the scoring method. Most
TGEs confirmed exclusively by the scoring method come
from the N-terminus truncated class (see Figure 4E), due
to non-identification of highly detectable peptides from the
truncated region. In summary, applying the TGE scoring
method has allowed us to promote several thousand puta-
tive protein variants (14% of the total) to a higher level of
confidence.
Shared TGEs among species
Only one TGE, histone H3 protein, is observed in all four
species––a Swiss-Prot protein for human and M. musculus
that is reported in TrEMBL for P. Alecto and A. Aegypti.
However, there are many TGEs in common between pairs
of species (Figure 5A), most of which are known proteins.
Some shared TGEs are classified as known in one species
but as novel isoform in another, for example three TGEs
that are known M. musculus proteins but have been classi-
fied as N-terminus truncated (two TGEs) and known pro-
tein with polymorphisms for human. The known protein
with polymorphism (Vesicle-trafficking protein SEC22b)
has unique peptide evidence for one of the polymorphisms.
Human also shares 116 identified TGEs with P. Alecto, al-
though none of these shared TGEs is a novel variant sup-
ported by peptide evidence. One novel isoform of Hetero-
geneous nuclear ribonucleoprotein D0 protein with pep-
tide evidence is shared between P. alecto and M. muscu-
lus (with unique peptide evidence in mouse). The distribu-
tion of knownM. musculus proteins shared with P. alecto is
shown in Supplementary Figure S6. Such identifications of
the same TGE in multiple species can increase confidence
in the biological validity of that identification, and are also
relevant to cross-species studies.
Novel TGEs
We identified novel TGEs in each dataset, from 32 in human
to 967 in P. alecto, but the majority are not supported by
unique peptide evidence (Table 1). In human andM.muscu-
lus,most putative novel TGEs are significantly shorter than
other TGE classes (Figure 5B). A large portion of novel P.
alecto TGEs are short but overall have median length close
to known proteins. Novel A. aegypti TGEs also have sim-
ilar median length compared to their known counterparts
but are not skewed towards shorter TGEs. Peptide cover-
age is similar or higher for novel TGEs (Figure 5C), giv-
ing confidence in these identifications. Collectively, this sug-
gests that most of the novel TGEs from P. alecto and A.
aegypti are likely to be newly discovered proteins, whereas
those fromM. musculus and human may be too short to be
functional proteins. This is confirmed by the fact that most
of the supposedly novel short human TGEs were found to
map directly to subsections of multiple existing proteins.
They exceed the BLAST e-value threshold because the sig-
nificance of individual matches decreases when there are
multiple matches, but they are very likely to be ORFs pre-
dicted from partially assembled transcripts.
CONCLUSION
The TGE classification pipeline presented here has been
shown to be a significant improvement in PITmethodology,
providing deeper insight into human samples, and finding
large numbers of confidently identified polymorphisms and
novel splice variants in non-model species that can be used
to rapidly improve their reference proteomes. For example,
strong evidence has been found for hundreds of novel TGEs
and protein isoforms in P. alecto and A. aegypti, including
many with alternative start codons. The significant reduc-
tion in putative TGEs seen when peptide evidence is consid-
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Figure 4. TGE scoring and validation. (A) Comparison of methods for confirming the identification of novel protein isoforms, applied to human PIT data.
A set of 197 known isoforms found in the sample using PIT was used for validation. The scoring method can identify 76 of these as isoforms, which is an
improvement over the 37 confirmed by the simple peptide evidence approach. (B) ROC curve showing performance of the scoring method in comparison
to the traditional variant-specific peptide evidence based method for known isoforms. (C) The number of TGEs classified as isoform rapidly decreases as
the threshold between TGE and reference score is increased, while the proportion of those that have been confirmed as isoforms present in the sample
increases. (D) Comparison of isoform classification techniques applied on novel isoforms from all species. The scoring method predicts higher numbers of
variant isoforms in the sample compared to the peptide evidence method, but misses some TGEs confirmed by peptide evidence. (E) Class distribution of
TGEs confirmed by the scoring method for novel isoforms in human.
ered demonstrates the benefit of using PIT rather than ex-
trapolating translated products from RNA-seq data alone.
By developing this pipeline and making it publicly available
we give the research community the opportunity to adopt
this alternative approach.
DATA AVAILABILITY
The software pipeline, and documentation, is available via
GitHub [https://github.com/bezzlab/TGEClassification].
The results generated, including novel protein sequences,
are available in PITDB ([http://pitdb.org] with experiment
accession numbers EXP000001, EXP000003, EXP000004
and EXP000008.
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Figure 5. (A) Overlap of all identified TGEs across organisms (to be classified as an overlap the TGEs were required to have identical sequences). Overlap-
ping TGEs are often known in one species but novel variant for the others. Some of the overlapping novel variants have variant-specific peptide evidence.
(B) Length distribution of different TGE classes identified from human,P. alecto,M.musculus andA. aegypti datasets. Novel TGEs are significantly shorter
than the rest of the TGE types for human and mouse, whileA. aegypti and P. alecto have novel TGEs with lengths similar to those of the other TGE classes.
(C) Distribution of peptide coverage per TGE for different TGE classes in each species.
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